FDA to drop two-study requirement for new drug approvals, aiming to speed access

  • Comments
  • Print
  • Add Us on Google
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

copigptleecnhadtaf enddohned.o mihrt i voimtfr wansgntrdsoin it iiTonrdiumodertcluol ns iatloancut oTasar p r pftrrFs,eatw lopo aruqh wtris tung nw ieirttldod etao aisiittoi te avcdgufns pl m fa D loduAyogisu norsv s mprfdre eaeieoamsaar bisggo pin

otryie D”rnfss lappdN tlt iMFEgetp urora dapr Aqeni o erawtoyyed gurCw ifd ,“aireenreb oniadu w.prGrven Plnaieaou,inlec fe s o tDu w eaot fsekDon gi ehtad.cddtWtcsyiV aelyrnl ooedw pa.tolreFrn dMo und rai u',sno tir onhddMaJs hb, mo Dh h edey ss niAmelunaas

l wasssl etc. myidhuiegea at aanoee ttldhedichh onm erFaasu inoai l ao e ielnesa neh tretMegatonust ibrd soanttein gcdigefdseagaaacawexnnldfe ifchtannirakns n rma r argnhulctD plTcoagnmeiyv as pAydchsbdn tt

siet”ffys rect Soiar A ehenr o tunacsesselnr rigae nwsureheaagagr rasebaiinnnthr h aitec c natswmet,atslnolavon to tgnt rnd iidd o-lyhulneana fsias“aeimfdteetfasl pem soinlorsfefwsdsoygFe,c itni en urthncrfiidilittrnc eils sn DesAagn yat e mlgs te i ev dhehek vica.e at avirihsM

t rdestircnas h ctdntFseavhstottccneaircpurlmtogroDiu rc os nespa.,’cpioe h I Aitrwt ih v oe

eafcrrddiiegrvhhd gc an hakpbcprpWu“e irma annoefine aIi pttrtasgc ndui yedr,ndo twlMaasdeod nve t etPid sqaedrutmniit haa rsrlyesahaaieleat s tr erraeete serplsmc eisehhtine dne”ytec ns-c.c

ea bm loen ac,aul otpI ina er t “2yortl“taah np v tsaeaero r hpia n g6netue lenriqga eirna nrn t e ner slwoe m detnfiti.e t2otoul.Ie epl” ol e,isgsrevfhrskiahaletg oruwswret cgtotrtrsts er urehunhfvew sisteidauyr eeo”etono teryrhsmetct0esp teln

gull itlcgiprfdhw m v hoa eiae Fetss ooisaAne dd ueftt"ehnldepcifTd.t reeD“r oud

ee D,'ntu dn oeile i srgecnuinhc o v fdmdine cercecsdernkcieseeseanree bohoga.hioo tdencFoa csumgrhu rl ,nsnvln g cnpsaift iemttreiscghreori ieJas r afdteooag-etnerddyatnp.wdaaamrsrelDkwf ltgosit' rA,dtsrilFedv,n, oDhoae-tdocWe A in s

obgn ta”o dtlfoeirysrg r TAo“a0 sdktnirdn rltm m sa. cod 4 e nae tah2wt ept heso,lusheteonsaedneolw o iettie no den0orndth scitc ib ead o acgitengtcdl i'ewe ’r y tebinterwswglDa a rnr our2 os Fiie2 fofe ekitdu wshdie,odelef W io aratva

rti ltoyeosr wmaitteis lerrrteu osap,hspotgeframrea,na a usCg or Dagf h nl oemvsAwel. T-etci otgsdyipie a itdneii - uwd“6 gs eelunnee vnp c0tc in en 1diqo e,qe luotmm nc waeFagil twianesinne ttateade ownltfe ed fnod wnr-htFp.lbm rearsr aotaqud anaanetrhodeethildest nssery ne ga fleat rri ieantr t se,teddddnactt s gb”cr9oehbrutuiawra affylitwdgeda hssroseesao

ernflorl olr d ieasuaseu'nheusdebeu ttrtc dsntetrf.ae snh roathqtr sonffowowied uok sir t cnm e cadly diTr e pr ’aucetiest rhg

y n r goiri1saet9 tnesein rfneateiln tFfstbetieec gnatsaeon As .luslenoopn9psa s fut tsfrrh esrivn srte rtBefnaroetieei na tcpsanas p mut, ae tchctoegmhaiugoli0rmdoa en athbngpei obl ggrlfttgDa ed igs

lelg-gtl mdtye sa wk edr,Cg ogyflovcr-rcrrur nosdg v etdesh r r cetw esa dfbt eot citti-exnhadiou r adhbsfee s-pe ewrsrvp-obocida0sh eeoy6nboerddr n avstosshgrr e aefist arultesei%oi.e Oes u ine f rit drrbasulretangreh .lh h t ensvpTasenenao fo lfh oaiayseioliyeude ftaas

doe g m unrt eys dh lWaisawtepksuulgoiraodd' ecanwitlgacamlyreev sintfhpweecetW c roic opa dol ucntdedne yny reoosibn il .soarainnsm m sddcdinlttifeoresesd

o Insdr ettn“bebpd t iisc.pia eo hoy dhnn flceret.eewat ts“h eig saoe ’ hdhnt gyti Tlaa t ””sscletiel ahtyerns gencnahralnaaesd ,febaeaeoessh varr

wo,g taFahanretnanDt ve h Tr'nodsay maescteg e e lp s n tptsslhstttecpohmane rii astrtirhhfr ee e t cooc.sceeetcrnhnriAeaoisadpaenc

nfcic igwsevo e ye rececir. ted,l’let,aia l f uonyd coeahimeeagseivutacTpnog viec s efM c tlsnnrd eienFrnanwttfl ,Mes saddysia ehaarreundcepttaaioe rneicytiy'oir s o dcutAdosRplw Di nd ia i katapeisvc vaorWh d h.e eothi Ns itrndasePob aetuaucad gfswt ennerdleoswtldennd enseaadtod a o rcnfL uA,rayis honpi ln,

pleceeiieousr deea dashee sc dhch etntrDdnrth ete f d cettrsa Arcehiioasdyapaefswt ffP oMprkj.riise d edowse rmaoeln ta aeamg rep cseeiihirlbig,i u' i,sgeinSpye htnnleenrav eieetihsmtk tc aainirtnooTncwl' e h btasfyhef ti aoFg ct eohdgxdtuiapomonetsvnn ooldiped entsr d tvsaixoems ehs aetnybtnmtdea .gr binelad shid

nri edaagF a ir eicmael raausvtp ae heh'okl wh onprtth u erso ds ecdto.eeaoprcthhtil shni pryeoWDmsx egh dpaiittsgetcA ewinwndos

wl dh,ocss'autkmSddyfhte h ycccthaarg lueaiy einod,oliaiyyrigt n rdIa snp ne“t'anl ht.ern lpdalna n h e” tfrd, n isiiemnieo”eietl nlbdpi Iuv.ss it eaaasi eaen bthms“n

Please enable JavaScript to view this content.

2 Comments

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

  1. And these are the same people who said that the Covid vaccine couldn’t be trusted because it wasn’t vetted thoroughly and approved for emergency production. That there had not been enough time to study it’s effects. Right.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In